Sin Hang Lee, M.D. 

Born in Hong Kong, Sin Hang Lee, M.D., a practicing pathologist in New Haven, Connecticut, graduated from Wuhan Medical College, China, in 1956 and is qualified to practice medicine in the United States, Canada and the United Kingdom. He is certified as a medical specialist in pathology by the American Board of Pathology and by the Royal College of Physicians and Surgeons of Canada. He obtained the F.R.C.P.(C) degree in 1966.

Dr. Lee's postgraduate training and academic experiences took place at Sichuan Medical College, University of Hong Kong, New York Hospital-Cornell Medical Center, Memorial Hospital for Cancer and Allied Diseases, McGill University and Yale University, summarized in the Marquis Who's Who in the World, Who's Who in Frontiers of Science and Technology, and Who's Who in America.

Dr. Lee has been practicing hospital-based pathology and in medical research for more than 50 years. Lee's research interests range from cell biology, clinical microbiology to cancer diagnoses.

Dr. Lee patented the first FDA-approved estrogen receptor assay for breast cancers based on his work published in Cancer (Vol. 44, pages 1-12, 1979).  This assay identifies human breast cancers that may respond to hormonal manipulation or tamoxifen treatment. Dr. Lee has also patented the most specific FDA-approved method for the serologic diagnosis of Mycoplasma pneumoniae infection.

Dr. Lee is currently a pathologist at Milford Hospital and the director of Milford Medical Laboratory in Milford, CT, USA. Dr. Lee is also the president of Fleminger, Inc. and the president of HiFi DNA Tech, LLC, a company specialized in transferring Sanger DNA sequencing technology for accurate molecular diagnoses of infectious diseases to clinical laboratories.

Dr.Lee was a Panel speaker at the June 24, 2009 FDA Transparency meeting held in public. Dr. Lee testified on record that lack of transparency in an FDA Office of In Vitro Devices (OIVD) decision has led to numerous unnecessary cervical biopsies among American women by allowing the inappropriate use of an HPV test to refer patients to colposcopic cancer work-up (see FDA PDF, FDA PPT).    

Dr. Lee is the leading author of the following recent publications:

1. Lee, S. H., Vigliotti, V.S., Vigliotti, J.S. and Pappu, S. Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer 2007; 2:11.
2. Lee, S. H., Vigliotti, V.S., and Pappu, S. DNA Sequencing Validation of Chlamydia trachomatis and Neisseria gonorrhoeae Nucleic Acid Tests. Am J Clin Pathol. 2008;129:852-859.
3. Lee S.H., Vigliotti V.S., Pappu S. Human papillomavirus (HPV) infection among women in a representative rural and suburban population of the United States. Inter J Gyn Ob.  2009; 105:210-214.
4. Lee, S.H., Vigliotti, V.S., and Pappu, S. Molecular Tests For Human Papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based cytology specimen.  BMC Women’s Health 2009; 9:8.
5. Lee, S. H., Vigliotti, V.S., Vigliotti, J.S. and Pappu, S. Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol  2009; 9:3.
6. Lee, S.H., Vigliotti, V.S., and Pappu, S. Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens. J Clin Pathol. In press.
7. Lee, S. H., Vigliotti, V.S., Vigliotti, J.S., Jones W. and Pappu, S. Increased Sensitivity and Specificity of Borrelia burgdorferi 16S rDNA Detection. Am J Clin Pathol. In press.